Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Finnigan, Paradigm Ink Metabolomics Partnership

NEW YORK, Nov. 6 — A division of Thermo Electron and Paradigm Genetics have formed a partnership to design new technologies for use in metabolomics, also known as the study of the interactions between small molecules, the companies said on Tuesday.

The companies plan to use chromatography and mass spectrometry systems to develop a new way to identify and validate metabolite biomarkers that they believe may be useful in drug discovery. 

Under the terms of the arrangement, Paradigm, of Research Triangle Park, NC, will provide technical consulting services in exchange for exclusive pre-commercial access to new systems made by Thermo Finnigan. Paradigm, which is publicly owned, specializes in functional genomics and metabolic profiling technologies. 

Financial terms of the agreement were not disclosed.

Thermo Finnigan, based in Waltham, Mass., specializes in mass spectrometers, chromatography systems, related software, and multi-instrument combinations of these products. 

The companies did not disclose any further financial details of the agreement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.